Praxis Precision Medicines, Inc. (PRAX): Shareholders' Equity
$878.14M
As of 2025-12-31
$1.34B
As of 2026-06-30
+126.0%
3-year compound annual growth
+25.0%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $878.14M | +97.1% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $445.45M | n/a | 2026-02-19, Balance as of period end |
| 2024-09-30 | $382.67M | n/a | 2025-02-28, Balance as of period end |
| 2024-06-30 | $419.10M | n/a | 2025-02-28, Balance as of period end |
| 2024-03-31 | $229.68M | n/a | 2025-02-28, Balance as of period end |
| 2023-12-31 | $69.67M | n/a | 2026-02-19, Balance as of period end |
| 2023-09-30 | $86.76M | n/a | 2025-02-28, Balance as of period end |
| 2023-06-30 | $105.62M | n/a | 2025-02-28, Balance as of period end |
| 2023-03-31 | $64.47M | n/a | 2025-02-28, Balance as of period end |
| 2022-12-31 | $76.11M | n/a | 2024-03-05, Balance as of period end |
| 2022-09-30 | $105.16M | n/a | 2024-03-05, Balance as of period end |
| 2022-06-30 | $138.87M | n/a | 2024-03-05, Balance as of period end |
| 2022-03-31 | $191.02M | n/a | 2024-03-05, Balance as of period end |
| 2021-12-31 | $250.81M | n/a | 2023-02-07, Balance as of period end |
| 2021-09-30 | $295.92M | n/a | 2023-02-07, Balance as of period end |
| 2021-06-30 | $333.77M | n/a | 2023-02-07, Balance as of period end |
| 2021-03-31 | $265.51M | n/a | 2023-02-07, Balance as of period end |
| 2020-12-31 | $287.46M | n/a | 2022-02-28, Balance as of period end |
| 2020-09-30 | -$123.26M | n/a | 2022-02-28, Balance as of period end |
| 2020-06-30 | -$104.08M | n/a | 2022-02-28, Balance as of period end |
| 2020-03-31 | -$90.76M | n/a | 2022-02-28, Balance as of period end |
| 2019-12-31 | -$81.01M | n/a | 2021-03-17, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Praxis Precision Medicines, Inc. (PRAX) | 2025-12-31 | $878.14M | +97.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare PRAX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗